Berlin, Germany
Berlin Cures AG has shared the latest insights from the Phase 2 trial of BC 007, an investigational therapy developed by Berlin Cures as a potential treatment for Long COVID. This randomized, double-blind trial has been pivotal in investigating BC 007’s safety and effectiveness.
The topline analysis of key study outcomes indicated that BC 007 did not demonstrate clear advantages over the placebo in treating Long COVID symptoms. While the primary endpoints did not show evidence of enhanced efficacy in the BC 007 treatment arms, both this study and previous research confirm the safety and tolerability of BC 007.
Due to financial constraints, Berlin Cures has had to make the difficult decision to halt all further studies and analyses at this stage. The team expresses deep gratitude to every patient, healthcare professional, and trial partner involved in this important effort.
This unfortunate news disappoints the hopes of many patients and researchers for a new, promising active treatment for Long COVID.
